Carlos Simón Selected Research

quinagolide

11/2011	The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis.
3/2011	Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia.
4/2010	The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlos Simón Research Topics

Disease

12	Ovarian Hyperstimulation Syndrome 09/2015 - 11/2002
10	Endometriosis 04/2017 - 01/2002
8	Neoplasms (Cancer) 12/2019 - 09/2007
7	Aneuploidy (Aneuploid) 01/2022 - 04/2016
6	Infertility (Sterility) 08/2021 - 10/2005
5	Spontaneous Abortion (Miscarriage) 01/2022 - 07/2005
5	Inflammation (Inflammations) 01/2021 - 03/2011
5	Leiomyoma (Uterine Fibroids) 10/2019 - 09/2008
4	Habitual Abortion (Recurrent Miscarriage) 08/2021 - 05/2003
4	Gynatresia 01/2020 - 09/2015
3	Pre-Eclampsia (Preeclampsia) 01/2022 - 06/2006
3	Reperfusion Injury 01/2021 - 04/2012
3	Lung Injury 01/2019 - 10/2014
3	Atrophy 05/2016 - 09/2015
3	Body Weight (Weight, Body) 06/2006 - 11/2003
3	Chromosome Aberrations (Chromosome Abnormalities) 10/2005 - 11/2003
2	Pain (Aches) 08/2021 - 05/2009
2	Edema (Dropsy) 01/2021 - 01/2019
2	Ischemia 01/2019 - 12/2014
2	Necrosis 01/2019 - 04/2012
2	Ectopic Pregnancy 01/2014 - 01/2014
2	Endometrial Neoplasms (Endometrial Cancer) 01/2013 - 01/2003
2	Melanoma (Melanoma, Malignant) 01/2012 - 11/2011
2	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 08/2011 - 06/2006
2	Ascites 04/2010 - 08/2007
2	Teratoma (Teratoid Tumor) 08/2008 - 07/2008
2	Male Infertility (Male Sterility) 11/2006 - 10/2005
1	Lung Neoplasms (Lung Cancer) 05/2022
1	Dyspnea (Shortness of Breath) 05/2022
1	Trisomy 18 Syndrome 09/2021
1	Uterine Hemorrhage (Uterine Bleeding) 08/2021
1	Endometritis 01/2021
1	Bacterial Vaginosis 01/2021
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2021
1	Dysbiosis 01/2020
1	Postoperative Pain 11/2019
1	Colorectal Neoplasms (Colorectal Cancer) 11/2019
1	Leiomyosarcoma 10/2019
1	Acute Kidney Injury (Acute Renal Failure) 05/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Fetal Growth Retardation (Intrauterine Growth Retardation) 01/2019

Drug/Important Bio-Agent (IBA)

11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2015 - 11/2002
7	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2012
6	Dopamine Agonists (Dopamine Agonist)IBA 11/2011 - 08/2007
5	Messenger RNA (mRNA)IBA 01/2014 - 01/2002
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2015
4	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2019
4	Lidocaine (Xylocaine)FDA LinkGeneric 01/2021 - 10/2014
4	Proteins (Proteins, Gene)FDA Link 04/2015 - 01/2003
4	LeptinIBA 06/2006 - 05/2004
3	Hormones (Hormone)IBA 08/2021 - 11/2010
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 04/2016
3	Prostaglandins DIBA 01/2017 - 04/2005
3	Dopamine Receptors (Dopamine Receptor)IBA 11/2014 - 03/2011
3	quinagolideIBA 11/2011 - 04/2010
3	Cabergoline FDA LinkGeneric 11/2011 - 08/2007
3	Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric 11/2010 - 11/2002
3	Estrogens (Estrogen)FDA Link 01/2010 - 10/2002
2	RNA (Ribonucleic Acid)IBA 10/2019 - 01/2012
2	CytokinesIBA 05/2019 - 10/2014
2	Interleukin-1 (Interleukin 1)IBA 01/2019 - 04/2012
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2017 - 04/2012
2	PolyethyleneimineIBA 02/2016 - 11/2015
2	Double-Stranded RNA (RNA, Double Stranded)IBA 02/2016 - 11/2015
2	Poly CIBA 02/2016 - 11/2015
2	polycationsIBA 02/2016 - 11/2015
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2012 - 11/2011
2	AlbuminsIBA 01/2012 - 11/2003
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2011 - 03/2011
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2021
1	AntigensIBA 01/2021
1	Coloring Agents (Dyes)IBA 01/2021
1	Bacterial ToxinsIBA 01/2021
1	Hematoxylin (Haematoxylon)IBA 01/2021
1	TransposasesIBA 01/2020
1	Biological FactorsIBA 01/2020
1	Circulating Tumor DNAIBA 12/2019
1	Formaldehyde (Formol)FDA Link 10/2019
1	NucleotidesIBA 10/2019
1	ParaffinIBA 10/2019
1	Indicators and Reagents (Reagents)IBA 05/2019
1	Interleukin-6 (Interleukin 6)IBA 05/2019
1	Anesthetics (Anesthetic Agents)IBA 01/2019
1	esmolol (Brevibloc)FDA LinkGeneric 01/2019
1	Tumor Biomarkers (Tumor Markers)IBA 01/2019
1	InterleukinsIBA 01/2019

Therapy/Procedure

6	Therapeutics 01/2022 - 07/2005
4	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2019 - 09/2015
3	Pneumonectomy (Lung Volume Reduction) 05/2022 - 09/2007
2	Uterine Myomectomy 10/2019 - 09/2008
2	Transplantation 02/2016 - 08/2008
2	Drug Therapy (Chemotherapy) 01/2012 - 01/2010
2	Thoracotomy 06/2011 - 05/2009
1	Lung Transplantation 01/2021
1	Complementary Therapies (Alternative Medicine) 01/2020
1	Enhanced Recovery After Surgery 11/2019
1	Morcellation 10/2019
1	Renal Replacement Therapy (Therapies, Renal Replacement) 05/2019
1	Length of Stay 05/2019
1	One-Lung Ventilation 01/2019